How are XPH strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the XPH strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 23.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$75.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a XPH strangle?

The breakeven for the XPH strangle priced on this page is roughly $62.25 and $69.75 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current XPH market-implied 1-standard-deviation expected move is approximately 6.82%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current XPH implied volatility affect this strangle?

XPH ATM IV is at 23.80% with IV rank near 31.65%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

XPH Strangle Strategy

XPH (State Street SPDR S&P Pharmaceuticals ETF), in the Financial Services sector, (Asset Management industry), listed on AMEX.

SPDR Series Trust - SPDR S&P Pharmaceuticals ETF is an exchange traded fund launched by State Street Global Advisors, Inc. It is managed by SSGA Funds Management, Inc. It invests in public equity markets of the United States. The fund invests in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences sectors. The fund invests in growth and value stocks of companies across diversified market capitalization. It seeks to track the performance of the S&P Pharmaceuticals Select Industry Index, by using representative sampling technique.

XPH (State Street SPDR S&P Pharmaceuticals ETF) trades in the Financial Services sector, specifically Asset Management, with a market capitalization of approximately $265.8M, a beta of 0.79 versus the broader market, a 52-week range of 40.38-65.98, average daily share volume of 61K, a public-listing history dating back to 2006. These structural characteristics shape how XPH etf options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.79 places XPH roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline. XPH pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.

What is a strangle on XPH?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current XPH snapshot

As of June 30, 2026, spot at $66.48, ATM IV 23.80%, IV rank 31.65%, expected move 6.82%. The strangle on XPH below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.

Why this strangle structure on XPH specifically: XPH IV at 23.80% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 6.82% (roughly $4.54 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated XPH expiries trade a higher absolute premium for lower per-day decay. Position sizing on XPH should anchor to the underlying notional of $66.48 per share and to the trader's directional view on XPH etf.

XPH strangle setup

The XPH strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With XPH near $66.48, the first option leg uses a $69.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed XPH chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 XPH shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$69.00	$0.49
Buy 1	Put	$63.00	$0.26

XPH strangle risk and reward

Net Premium / Debit: -$75.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$75.00
Breakeven(s): $62.25, $69.75
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

XPH strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on XPH. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$6,224.00
$14.71	-77.9%	+$4,754.20
$29.41	-55.8%	+$3,284.40
$44.10	-33.7%	+$1,814.60
$58.80	-11.5%	+$344.80
$73.50	+10.6%	+$374.99
$88.20	+32.7%	+$1,844.79
$102.90	+54.8%	+$3,314.59
$117.59	+76.9%	+$4,784.39
$132.29	+99.0%	+$6,254.19

When traders use strangle on XPH

Strangles on XPH are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the XPH chain.

XPH thesis for this strangle

The market-implied 1-standard-deviation range for XPH extends from approximately $61.94 on the downside to $71.02 on the upside. A XPH long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current XPH IV rank near 31.65% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on XPH should anchor more to the directional view and the expected-move geometry. As a Financial Services name, XPH options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to XPH-specific events.

XPH strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. XPH positions also carry Financial Services sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move XPH alongside the broader basket even when XPH-specific fundamentals are unchanged. Always rebuild the position from current XPH chain quotes before placing a trade.

Frequently asked questions

What is a strangle on XPH?: A strangle on XPH is the strangle strategy applied to XPH (etf). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With XPH etf trading near $66.48, the strikes shown on this page are snapped to the nearest listed XPH chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are XPH strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the XPH strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 23.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$75.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a XPH strangle?: The breakeven for the XPH strangle priced on this page is roughly $62.25 and $69.75 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current XPH market-implied 1-standard-deviation expected move is approximately 6.82%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on XPH?: Strangles on XPH are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the XPH chain.
How does current XPH implied volatility affect this strangle?: XPH ATM IV is at 23.80% with IV rank near 31.65%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.